View Older Stories View More Recent Stories
-
Barclays Reiterates Equalweight Rating on Kenvue Inc (KVUE)
-
Kenvue Inc (KVUE) PT Lowered to $18 at Evercore ISI
-
US Advises Pregnant Women To Avoid Tylenol Over Fears Of Autism
-
Kenvue stock falls after report of Trump admin linking Tylenol to autism
-
Should you buy a dip in Kenvue stock? Jefferies weighs in
-
Goldman Sachs on Kenvue Inc (KVUE): 'We believe this news flow could pose reputational risk'
-
JPMorgan Defending Kenvue Inc (KVUE): 'Tylenol products already direct patients who are pregnant or breastfeeding to consult their healthcare provider before use'
-
Canaccord Genuity Defending on Kenvue Inc (KVUE), PT $26, 'Actual risk to KVUE should be minimal'
-
Kenvue Inc (KVUE) PT Lowered to $20 at Deutsche Bank
-
Kenvue Inc (KVUE) PT Lowered to $23 at Evercore ISI, 'Is the sell-off overdone?'
-
UBS Negative on Kenvue Inc (KVUE)
-
Kenvue (KVUE) call put ratio 1.6 calls to 1 put amid wide price movement
-
Evercore ISI: 'Tylenol constitutes a key profit center and sits at the core of Kenvue’s strategic value'
-
BofA Securities Defending Kenvue Inc (KVUE): 'We estimate Tylenol represents ~9% of KVUE’s sales', Sees 'widening discount as a particularly attractive entry point'
-
HHS spokesperson to CNBC on forthcoming autism report - until we release final report, claims about its contents are nothing more than speculation
-
HHS: Claims About Report Tying Tylenol To Autism "Speculation" - Bloomberg
-
RBC Capital on Kenvue Inc (KVUE): 'The scientific link between acetaminophen and autism/ADHD remains unproven'
-
Kenvue (KVUE) responding to WSJ report: continue to believe there is no casual link between acetaminophen use during pregnancy and autism - CNBC
-
RFJ Jr., HHS to link autism to Tylenol use in pregnancy and folate deficiencies - WSJ
-
Starboard Releases 13F, Shows Two New Stakes
-
Kenvue Inc (KVUE) PT Lowered to $22 at RBC Capital
-
Kenvue Inc (KVUE) PT Lowered to $25 at Jefferies
-
Kenvue Inc (KVUE) PT Lowered to $26 at Canaccord Genuity
-
Kenvue Inc. (KVUE) Misses Q3 EPS by 6c, Misses on Revenue; Offers FY25 EPS Guidance
-
Kenvue (KVUE) Declares $0.2075 Quarterly Dividend; 3.7% Yield
-
Kenvue (KVUE) call put ratio 1 call to 1.1 puts on active option volume of 111K contracts
-
Kenvue Inc (KVUE) PT Lowered to $22 at Citi
-
UBS Reiterates Neutral Rating on Kenvue Inc (KVUE)
-
Goldman Sachs Reiterates Neutral Rating on Kenvue Inc (KVUE)
-
Citi on Kenvue Inc (KVUE): 'We expect a positive reaction today to the news'
-
Kenvue appoints Kirk Perry as interim CEO, reviews strategic alternatives
-
Kenvue Releases Second Annual Healthy Lives Mission Report Highlighting Progress in Reducing Emissions and Advancing More Sustainable Product Innovation
-
Kenvue (KVUE) Announces Resignation of Ellie Bing Xie, Group President, Asia Pacific
-
Wells Fargo sees second-half rebound for software stocks, upgrades Zscaler
-
Kenvue (KVUE) considers selling skin health and beauty brands, sources say - Reuters
-
Goldman Sachs Reiterates Neutral Rating on Kenvue Inc (KVUE)
-
Buy the dip in Kenvue stock: Jefferies
-
Jefferies Reiterates Buy Rating on Kenvue Inc (KVUE)
-
Kenvue (KVUE) Debuts on Fortune 500 List
-
Piper Sandler: 'What Are Ingredient Players Saying for Beauty in CQ1?'
-
Canaccord Genuity Reiterates Buy Rating on Kenvue Inc (KVUE)
-
Kenvue Inc (KVUE) PT Raised to $24.50 at Citi
-
Kenvue Inc. (KVUE) Tops Q2 EPS by 1c; updates outlook
-
Kenvue (KVUE) Announces CFO Change
-
Kenvue (KVUE) spreaders active in May 9 weekly 24, May 24 calls, September 23 and September 25 calls into quarter results
-
Kenvue (KVUE) on watch on positive ruling
-
Third Point Builds Stake in Kenvue (KVUE) - FT
-
Redburn-Atlantic Starts Kenvue Inc (KVUE) at Neutral
-
Piper Sandler's Beauty & Wellness Teen Survey: 'Don't See a Beauty Slowdown in Teens'
-
What's next for Johnson and Johnson after third failed attempt to settle talc laws
